(Q47429067)

16 January 2018

title

Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL. (English)

1 reference

16 January 2018

author

Olivier Hermine

13

1 reference

16 January 2018

Arnaud Petit

object named as

A Petit

9

0 references

author name string

L Lhermitte

1

1 reference

16 January 2018

R Ben Abdelali

2

1 reference

16 January 2018

P Villarèse

3

1 reference

16 January 2018

N Bedjaoui

4

1 reference

16 January 2018

V Guillemot

5

1 reference

16 January 2018

A Trinquand

6

1 reference

16 January 2018

M Libura

7

1 reference

16 January 2018

A S Bedin

8

1 reference

16 January 2018

H Dombret

10

1 reference

16 January 2018

G Leverger

11

1 reference

16 January 2018

N Ifrah

12

1 reference

16 January 2018

E Macintyre

14

1 reference

16 January 2018

V Asnafi

15

1 reference

16 January 2018

publication date

3 July 2012

1 reference

16 January 2018

published in

Leukemia

1 reference

16 January 2018

volume

27

1 reference

16 January 2018

issue

2

1 reference

16 January 2018

page(s)

305-314

1 reference

16 January 2018

https://scigraph.springernature.com/pub.10.1038/leu.2012.177

exact match

0 references

cites work

Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Cluster analysis and display of genome-wide expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

7 January 2021

Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

7 January 2021

Web-based analysis and publication of flow cytometry experiments

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.177

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.177

1 reference

16 January 2018

1 reference

16 January 2018